Mundipharma (United Kingdom)
- World rank, all time
- #24,849 of 42,892
- Rank in United Kingdom
- #1,325 of 2,253
- Research works
- 209 ▼ 31% vs 2013–17
- Citations
- 6.5k 31.0 per fractional work
- Top-10% rate
- 11.3% record average 16.5%
- Open access
- 45% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 6.2×. Every wedge is a field page.
- Pharmacology, Toxicology and Pharmaceutics 6.2×
- Veterinary 3.6×
- Biochemistry, Genetics and Molecular Biology 2.8×
- Medicine 2.5×
- Immunology and Microbiology 2.4×
- Chemistry 2.1×
- Earth and Planetary Sciences 1.9×
- Economics, Econometrics and Finance 1.4×
- Physics and Astronomy 1.4×
- Materials Science 0.9×
- Chemical Engineering 0.7×
- Health Professions 0.6×
- Decision Sciences 0.6×
- Arts and Humanities 0.4×
- Environmental Science 0.3×
- Psychology 0.3×
- Social Sciences 0.3×
- Agricultural and Biological Sciences 0.3×
- Engineering 0.2×
- Computer Science 0.2×
- Business, Management and Accounting 0.1×
Which keywords describe research at Mundipharma (United Kingdom)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Epidemiology, Antifungal Therapy, Breast Cancer, Tumor Microenvironment, Immunocompromised Patients, Candidiasis, Invasive Fungal Infections and Immunotherapy.
- Quinoxaline
- Health Biotechnology
- Glacier
- Cost-effectiveness Analysis
- Astrobiology
- Warburg Effect
- Lymphoma
- HIF-1
- Entrepreneurship
- Treatment
- Monoclonal Antibodies
- HER2
- Tumor Regression
- Chemotherapy
- Gene Therapy
- Candidiasis
- Immunotherapy
- Breast Cancer
- Antifungal Therapy
- Epidemiology
- Inflammation
- Immunocompromised Patients
- Tumor Microenvironment
- Invasive Fungal Infections
- Synthesis
- Monoclonal Antibody
- Diagnosis
- Medicinal Chemistry
- Trastuzumab
- Cancer
- Climate Change
- Intellectual Property
- Quality of Life
- Antimicrobial Activity
- Capacity Building
- Extraterrestrial Life
- Global Collaboration
- Health Utility Measures
- Water Availability
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 39 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 39 words, with their numbers
- Epidemiology4▲ 2.8×17 topics
- Antifungal Therapy2▲ 66×3 topics
- Inflammation2▲ 2.6×8 topics
- Breast Cancer2▲ 22×3 topics
- Immunocompromised Patients2▲ 87×2 topics
- Immunotherapy2▲ 7.0×6 topics
- Tumor Microenvironment2▲ 12×3 topics
- Candidiasis2▲ 103×1 topic
- Invasive Fungal Infections2▲ 127×1 topic
- Gene Therapy2▲ 24×4 topics
- Synthesis2▲ 12×3 topics
- Chemotherapy1▲ 5.9×2 topics
- Monoclonal Antibody1▲ 81×2 topics
- Tumor Regression1▲ 39×2 topics
- Diagnosis1▲ 4.3×8 topics
- HER21▲ 140×1 topic
- Medicinal Chemistry1▲ 14×2 topics
- Monoclonal Antibodies1▲ 45×3 topics
- Trastuzumab1▲ 88×1 topic
- Treatment1▲ 3.2×9 topics
- Cancer1▲ 2.7×6 topics
- Entrepreneurship1▲ 9.1×2 topics
- Climate Change1▲ 1.18×2 topics
- HIF-11▲ 55×1 topic
- Intellectual Property1▲ 28×2 topics
- Lymphoma1▲ 20×3 topics
- Quality of Life1▲ 2.4×4 topics
- Warburg Effect1▲ 55×1 topic
- Antimicrobial Activity1▲ 18×1 topic
- Astrobiology1▲ 104×1 topic
- Capacity Building1▲ 51×2 topics
- Cost-effectiveness Analysis1▲ 35×1 topic
- Extraterrestrial Life1▲ 143×1 topic
- Glacier1▲ 69×1 topic
- Global Collaboration1▲ 91×1 topic
- Health Biotechnology1▲ 198×1 topic
- Health Utility Measures1▲ 35×1 topic
- Quinoxaline1▲ 142×1 topic
- Water Availability1▲ 69×1 topic
Which research topics does Mundipharma (United Kingdom) publish most on?
By volume in 2022–2025: Antifungal resistance and susceptibility, HER2/EGFR in Cancer Research, Cancer, Hypoxia, and Metabolism and Cryospheric studies and observations.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Antifungal resistance and susceptibility Infectious Diseases 2 works
- 2 HER2/EGFR in Cancer Research Oncology 1 works
- 3 Cancer, Hypoxia, and Metabolism Cancer Research 1 works
- 4 Cryospheric studies and observations Atmospheric Science 1 works
- 5 Biotechnology and Related Fields Public Health, Environmental and Occupational Health 1 works
- 6 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
- 7 Synthesis and Biological Evaluation Organic Chemistry 1 works
- 8 Space Science and Extraterrestrial Life Astronomy and Astrophysics 1 works
- 9 CAR-T cell therapy research Oncology 1 works
- 10 RNA Interference and Gene Delivery Molecular Biology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Mundipharma (United Kingdom)'s research output changed?
Output in 2018–2022 was 31% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Cambridge
- University of Cambridge
- Addenbrooke's Hospital
- MRC Laboratory of Molecular Biology
- Anglia Ruskin University
- AstraZeneca (United Kingdom)
- Microsoft Research (United Kingdom)
- British Antarctic Survey
- Cambridge University Hospitals NHS Foundation Trust
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.